| Trial ID: | L5749 |
| Source ID: | NCT01497600
|
| Associated Drug: |
Insulin Detemir
|
| Title: |
Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: insulin detemir|DRUG: insulin NPH
|
| Outcome Measures: |
Primary: Area under the glucose infusion rate curve | Secondary: Maximum glucose infusion rate|Time to maximum glucose infusion rate.|Area under the serum insulin curve|Maximum serum insulin concentration|Time to maximum insulin concentration|Terminal rate constant of insulin|Terminal half-life of insulin|Adverse events
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2004-02
|
| Completion Date: |
2004-08
|
| Results First Posted: |
|
| Last Update Posted: |
2017-01-27
|
| Locations: |
Novo Nordisk Investigational Site, Chula Vista, California, 91911, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01497600
|
